Dr Steven Knapper
Projects as PI
2 of 6
- A phase 2, randomized, biomarker-driven, clinical study in patients with relapsed or refractory AML with an exploratory arm in patients with newly diagnosed high-risk AML and exploratory arms with varying levels of MCL-1 dependence (13/06/2019 - 30/06/2023)
- A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat in chronic myelomonocytic leukaemia (01/07/2015 - 30/11/2019)
- A phase 3 multicenter randomised, double blind placebo-controlled trial of the FLT3 inhibitor Gilternib (ASP2215) administered as maintenance therapy following induction/consolidation for subjects with FLT3/ITD AML in the first complete remission (29/09/2017 - 31/01/2024)
- A phase 3 open label randomised study of AC220 monotherapy vs salvage chemotherapy in subjects with FLT3-ITD positive AML refractory to or replaces after first line treatment with or without haematopoietic stem cell (01/12/2014 - 30/06/2017)
- A phase 3 randomised, double blind, active controlled study evaluating momelotinib versus ruxolitinib insubjects with primary myelofibrosis (PMF) or post-polycythermia vera or post essential thrombocythermia myelofibrosis (01/08/2015 - 31/12/2016)
Projects as Co-Investigator
1 of 3
- AML 18 - A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome (01/06/2013 - 31/07/2024)
- An open label, multicentre phase 1 study to characterize the safety, tolerability, preliminary anti tumour activity, PK and MTD of Bayer 125152 in patients with advanced haematological malignancies (15/12/2016 - 15/11/2018)
- A study of the selective inhibitor or nuclear export selinexor (KTP-330) versus specified physician's choice in patient >60 years old with relapsed/refractory acute myeloid leukaemia who are ineligible for intensive chemotherapy/transplantation (11/10/2017 - 30/11/2017)
- CReSt catalytic funding bid (01/04/2023 - 31/03/2025)
- Development on an in vivo pre-clinical model to test the blockade of CD200-CD200R using a fully humanised anti-CD200 antibody for the treatment of patients with acute myeloid leukaemia (01/10/2016 - 28/02/2018)
